Clinical Pharmacists’ Knowledge of and Attitudes toward Pharmacogenomic Testing in China

Nie, Xiaoyan; Jia, Ting; Hu, Xiaowen; Li, Sicong; Zhang, Xinyi; Wu, Caiying; Zhang, Yuqing; Chen, Jing; Shi, Luwen; Lu, Christine Y.

doi:10.3390/jpm12081348

Cited by 3 publications

(1 citation statement)

References 38 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Breadth of literature tackled the attitude and involvement of pharmacists in genetic testing and voiced their concerns regarding primary genetic testing [ 23 – 29 ] and even a review by Mills and Haga (2013) proposed a collaboration among genetic counselors and pharmacists to aid in the thorough counseling of genetic test results [ 30 ]. However, paucity of studies addressed the attitude of pharmacists toward secondary findings.…”

Section: Introductionmentioning

confidence: 99%

The attitude and behaviors of the different spheres of the community of the United Arab Emirates toward the clinical utility and bioethics of secondary genetic findings: a cross-sectional study

Rahma,

Abdullahi,

Graziano

et al. 2023

Hum Genomics

View full text Add to dashboard Cite

Introduction Genome sequencing has utility, however, it may reveal secondary findings. While Western bioethicists have been occupied with managing secondary findings, specialists’ attention in the Arabic countries has not yet been captured. We aim to explore the attitude of the United Arab Emirates (UAE) population toward secondary findings. Method We conducted a cross-sectional study between July and December 2022. The validated questionnaire was administered in English. The questionnaire consists of six sections addressing topics such as demographics, reactions to hypothetical genetic test results, disclosure of mutations to family members, willingness to seek genetic testing, and attitudes toward consanguinity. Chi-squared and Fisher’s exact tests were used to investigate associations between categorical variables. Results We had 343 participants of which the majority were female (67%). About four-fifths (82%) were willing to know the secondary findings, whether the condition has treatment or not. The most likely action to take among the participants was to know the secondary findings, so they can make life choices (61%). Conclusion These results can construct the framework of the bioethics of disclosing secondary findings in the Arab regions.

show abstract

Section: Introductionmentioning

confidence: 99%

The attitude and behaviors of the different spheres of the community of the United Arab Emirates toward the clinical utility and bioethics of secondary genetic findings: a cross-sectional study

Rahma,

Abdullahi,

Graziano

et al. 2023

Hum Genomics

View full text Add to dashboard Cite

show abstract

Clinical pharmacists’ knowledge, attitude, perception, and beliefs about the role of pharmacogenetic testing for genes polymorphisms when prescribing mercaptopurine

Abanmy,

Alghamdi,

Aljudaie

et al. 2024

Saudi Pharmaceutical Journal

View full text Add to dashboard Cite

Physicians’ Knowledge, Attitude, and Experience of Pharmacogenomic Testing in China

Jia

et al. 2022

JPM

View full text Add to dashboard Cite

(1) Background: As prescribers, physicians play a decisive role in applying and promoting pharmacogenomic (PGx) testing in clinical practices. So far, little is known about physicians’ perspectives on PGx testing in China. The aim of this study was to assess physicians’ knowledge of, attitude towards, and experience of PGx testing in China. (2) Methods: A 39-question online survey was developed. Participants were physicians recruited through two platforms, MEDLINKER and “Dazhuanjia”. (3) Results: A total of 450 respondents completed the survey and 366 questionnaires were eligible for analysis based on the inclusion criteria. Among all included physicians, 275 (75.1%) had heard of PGx testing before. More than half rated their knowledge of PGx testing as “Fair” (61.5%) while 20.0% chose “Excellent” or “Good” and 18.6% chose “Poor” or “Terrible”. “Guidelines, consensus, and treatment paths for disease diagnosis and treatment” (72.7%) were the most preferred sources of information about PGx testing. Respondents were confident in their personal capacity to conduct PGx, with an average score of 3.30 ± 0.09 (out of 5.00). Most respondents (75.6%) believed that PGx could “help to improve efficacy and reduce the incidence of adverse reactions”. Targeted cancer therapy (score 78.95 ± 1.26 out of 100) was considered the field where PGx testing had its highest value. Lack of professionals and knowledge (n = 186, 67.6%), high costs of testing (n = 170, 61.8%), and lack of hospitals to offer PGx testing (n = 166, 60.4%) were identified as the primary obstacles to increasing the uptake of PGx testing in China. Academic conference (n = 213, 72.4%) was considered the most efficient way for physicians to obtain information about PGx testing. (4) Conclusions: Physicians in China have poor knowledge about PGx testing; nonetheless, they generally had confidence in their capacity to order PGx testing and positive attitudes towards the use of PGx testing in routine clinical practices. Future efforts to promote the uptake of PGx testing should focus on foundational education and practical training.

show abstract

Clinical Pharmacists’ Knowledge of and Attitudes toward Pharmacogenomic Testing in China

Cited by 3 publications

References 38 publications

The attitude and behaviors of the different spheres of the community of the United Arab Emirates toward the clinical utility and bioethics of secondary genetic findings: a cross-sectional study

The attitude and behaviors of the different spheres of the community of the United Arab Emirates toward the clinical utility and bioethics of secondary genetic findings: a cross-sectional study

Clinical pharmacists’ knowledge, attitude, perception, and beliefs about the role of pharmacogenetic testing for genes polymorphisms when prescribing mercaptopurine

Physicians’ Knowledge, Attitude, and Experience of Pharmacogenomic Testing in China

Contact Info

Product

Resources

About